The Cost-Effectiveness of Dabigatran and the Opportunity Cost of Delayed Subsidised Access in Australia

Value in Health - United Kingdom
doi 10.1016/j.jval.2013.08.1285
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV